Bladder tumor markers: need, nature and application. 1. Nucleus-based markers.
Urothelial tumors are common: their diagnosis and long-term management represent a large part of most urologists' workload. The majority of such tumors are 'superficial' and are mostly managed by repeated cystoscopic surveillance and treatment. A smaller but significant group of patients either start with, or subsequently progress to, more invasive disease, thus requiring an alternative and more invasive treatment. Maximizing the benefit/risk ratio of the diagnosis and the various treatment options of bladder tumors requires the availability of a reliable tumor marker. The concept of tumor markers encompasses the utilization of any detectable deviation from normality that is indicative of neoplasia. For bladder cancer, most of these markers are present in urine. In this part of the review we examine, from the clinician's point of view, the literature verdict on older techniques such as cytology and cytometry, as well as the current status of new nucleus-based tests such as P53, telomerase, NMP22 and Ki67.
Kirollos
M M
MM
Urology Department, Torbay Hospital, South Devon Health Care Trust, UK.
McDermott
S
S
Bradbrook
R A
RA
D014408:Biomarkers, Tumor / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis
D014408:Biomarkers, Tumor